ArticleMolecular oncology2018

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.

Ines De Pauw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.